

Delivering Trusted Expertise & Enrollment Success in Cardiometabolic Research

DelRicht Research combines deep therapeutic expertise with proven operational success across cardiometabolic trials. Our physician-led network is embedded within diverse communities, enabling rapid enrollment and high-quality data capture across complex and sensitive protocols.

14+ Cardiometabolic Trials
in The Past 6 Years

450+ Participants Enrolled
in Cardiometabolic Studies

17 Sites Nationwide
Experienced in Cardiometabolic Trials

Why Choose DelRicht for Cardiometabolic Trials




Experience Across Indications:

Trials completed in obesity, T2DM, metabolic syndrome, weight management, hypertension, MASH, diabetic neuropathy, and more.



Diverse Patient Access:

Sites embedded within high-volume physician clinics to access underserved patient populations, with **45%+ average diversity across sites.**



Proven Performance: DelRicht consistently demonstrates success in Phase II-III cardiometabolic trials, including **top enroller status achieved in 3 studies** over the past 5 years. **DelRicht also supported the FDA approval of farxiga** by AstraZeneca.

1 

Type 2 Diabetes
FDA Approval

farxiga

3 

Studies with Top
Enroller Status

Network Capabilities

Trusted Investigators Nationwide:

Our principal investigators are **experts in cardiometabolic trials**, spanning GLP-1 toxicity management, dose titration, while ensuring high retention through education.

17 Experienced Sites with Full-Service Infrastructure:

Our sites are equipped with access to local **labs, secure standardized IP storage, dietitian access, and specialty care providers.**

17 

Experienced
Investigators

Integrated Patient Support for Retention and Compliance:

Dedicated, full-time site staff provide extensive cardiometabolic education, real-time consent support and adherence follow-up.

Access to Priority Cohorts:

Our high-volume, embedded sites provide direct **access to high-value cardiometabolic cohorts**, including incretin-naïve and interconnected conditions such as T2DM and obesity.

320+

Yrs Collective
PI Experience

Let's Talk About Your Next Cardiometabolic Trial

DelRicht Research is ready to support your upcoming study with the experience, infrastructure, predictability, and speed you need to succeed. From study start-up to enrollment and retention, our teams are built to deliver quality results.